Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0000950170-23-014782
Filing Date
2023-04-26
Accepted
2023-04-26 16:04:11
Documents
6
Period of Report
2023-06-07

Document Format Files

Seq Description Document Type Size
1 DEF 14A dice-def_14a-2022_proxy.htm DEF 14A 989213
2 GRAPHIC img82331100_0.jpg GRAPHIC 54896
3 GRAPHIC img82331100_1.jpg GRAPHIC 9936
4 GRAPHIC img82331100_2.jpg GRAPHIC 9936
5 GRAPHIC img82331100_3.jpg GRAPHIC 144921
6 GRAPHIC img82331100_4.jpg GRAPHIC 110912
  Complete submission text file 0000950170-23-014782.txt   1446265
Mailing Address 400 EAST JAMIE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080
Business Address 400 EAST JAMIE COURT SUITE 300 SOUTH SAN FRANCISCO CA 94080 650-566-1402
DICE Therapeutics, Inc. (Filer) CIK: 0001645569 (see all company filings)

EIN.: 472286244 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-40794 | Film No.: 23849669
SIC: 2834 Pharmaceutical Preparations